TMCnet News
OTCtipReporter.com: OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), Amwest Imaging Incorporated (OTCBB: AMWI), Umami Sustainable Seafood Inc. (OTCBB: UMAM): Sign up for our FREE Stock Picks Today!(M2 PressWIRE Via Acquire Media NewsEdge) Join us at www.OTCtipReporter.com for a complimentary subscription to the most exciting online financial newsletter. ___________________________________________________________________________ Find out the Buzz on all the Hottest stocks at: http://www.OTCtipReporter.com OncoVista Innovative Therapies Engages Oncology Therapeutic Development to Initiate a Phase Ib Study of Cordycepin in Patients With Refractory TdT Positive Leukemia SAN ANTONIO, TX -- 11/28/11 -- OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies with reduced toxicity and improved patient safety, announced today that it has entered into an agreement with Oncology Therapeutic Development (OTD), a consulting and early Clinical Development focused CRO, to initiate a Phase Ib clinical trial of Cordycepin associated to Pentostatin for the treatment of patients with terminal deoxynucleotidyl transferase (TdT)-positive refractory leukemia. The goals of this collaboration project are to quickly and economically complete the Phase Ib development step, through the intracellular and plasma real time PK/PD assessment to optimize the dose and scheduling of both Cordycepin and Pentostatin. "We have engaged OTD and its consultant's team to initiate a Phase Ib trial of Cordycepin. We are excited because Prof. Esteban Cvitkovic and his team have been instrumental in the development of several successfully registered anticancer agents such as Cisplatin, Oxaliplatin, Amifostine, Irinotecan, Docetaxel and ET-743s," stated Alexander L. Weis, Ph.D., President and Chief Executive Officer of OncoVista Innovative Therapies. OncoVista has received Orphan Drug Designation from the FDA for Cordycepin in this indication, which affords the company seven years of market exclusivity once the drug is approved for this indication. About cordycepin and TdT positive leukemias Cordycepin (3'-deoxyadenosine) is a nucleoside analog that has been shown in preclinical studies to have activity against TdT-positive cells. Expression of TdT is one of the hallmarks of acute lymphoblastic leukemia (ALL). In addition to ALL patients, subsets of patients with acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) also express the TdT enzyme. Patients who have TdT-positive leukemia (ALL, AML, or blastic CML) which have failed at least one standard treatment regimen and for which no standard therapies are expected to result in durable remission are eligible for enrollment in this trial. About OncoVista Innovative Therapies OncoVista is a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies which are more efficacious and less toxic. Further information on OncoVista can be found atwww.oncovista.com. Forward-Looking Statements: A number of statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. These risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. ___________________________________________________________________________ Visit www.OTCtipReporter.com Amwest Announces Launch of Downloadable 256 AES Encryption for RIM's BlackBerry via App World LOS ANGELES, CA -- 11/28/11 -- Amwest Imaging Incorporated (OTCBB: AMWI) is pleased to announce the launch and final stages of completion of beta development for the application of Zipclik software for the BlackBerry Mobile Device ("BlackBerry") by Research in Motion. ZipClik for BlackBerry will be released to an estimated 32 Million BlackBerry users World Wide via App World. BlackBerry users will then be able to enjoy secure and encrypted phone calls, Instant messaging, data transfer, and VOIP communication through the 256 bit key encryption offered by ZipClik for $99 USD. "This additional roughly $3.2 Billion Dollar potential new target customer again validates Amwest's purchase and further development of the Zipclik technology," stated CEO Jason Gerteisen. BlackBerry commands a 11.7% share of worldwide smartphone sales, making it the fourth most popular device manufacturer, though reports show BlackBerry users to be the most conscious of security. The consumer BlackBerry Internet Service is available in 91 countries worldwide on over 500 mobile service operators using various mobile technologies. As of October 2011, there were seventy million subscribers worldwide to BlackBerry, and now BlackBerry Tablet users. Zipclik Technologies is a 256 AES Key encryption software for Skype, AIM, Yahoo IM, Meebo, Trillian, and other Voice Over Internet, Messaging, Instant messaging and Internet file transfer Protocols ("VOIP") Software. The "256 AES key" is now available through the website www.zipclik.com. The software works by providing a 256 AES key encryption at the time a conversation message or file transfer starts. In addition; exponential coverage occurs when the recipient of the data stream utilizes Zipclik on the opposite side of the transmission making the code virtually "unbreakable" or "hackable." This software is essential and necessary for clients wanting to protect and privatize financial data, medical information, enterprise research, sensitive corporate directives, passwords, and all other confidential, and sensitive information. The zipclik encryption software provides a military grade security not only for voice messaging, file transfer; but also ensures any and all transmission left on any hosts server will remain encrypted to protect all information from any third party, hacking, or unauthorized dissemination. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words or phrases "would be," "would allow," "intends to", "will likely result," "are expected to," "will continue," "anticipate," "expect," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "considers," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These include the company's historic lack of profitability, end user customer acceptance and actual demand, which may differ significantly from expectations, the need for the company to manage its growth, the need to raise funds for operations and other risks within the regulation of the industry. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, events or circumstances after the date of such statement. ___________________________________________________________________________ Visit www.OTCtipReporter.com Umami Sells and Delivers Bluefin Tuna Worth Approximately $50 Million SAN DIEGO, November 29, 2011 - Umami Sustainable Seafood Inc. (OTCBB: UMAM) First Phase of Harvesting of FY ending June 2012 Finalized o Tuna Prices Increase 38% From Last Harvesting SeasonUmami Sustainable Seafood Inc. (OTCBB:UMAM) ("Umami" or the "Company"), a holding company of fish farms supplying sashimi-grade Northern Bluefin Tuna to the global market, is pleased to announce that its subsidiary Baja Aqua Farms has sold and delivered approximately $50 million worth of tuna harvested atBaja's Mexican facility. The sales reflect an increase of 38% in the price paid per kilo of tuna compared to the price paid for tuna in the last fiscal year. Harvesting at Baja began in late August 2011 and finished last week. Traditionally, harvesting at Baja takes place from November to March, but the new harvesting schedule provides our clients with additional options going forward. Harvesting at Kali Tuna, Umami's Croatian operation, is planned to start in December, and is projected to be substantially complete by early March 2012. Oli Steindorsson, Chairman and Chief Executive of Umami, commented: "The successful change in of Baja's harvesting schedule is another example of why the merger of the Kali andBaja operations is beneficial. Umami can now offer its clients premium sashimi-grade Bluefin Tuna eight months out of every year, instead of the previous three month window. It also means that Umami's annual cash flows are stabilizing and the company will become less dependent on short-term debt. In addition to the 38% rise in tuna prices this year as compared to last year, improvement in our operations and other factors have helped to improve our profit margin on sales contracts. We are especially pleased that our fish farming process has matured enough so that we are now able to shift and extend our harvest schedule in order to take maximum advantage of current market conditions." About Umami Sustainable Seafood Inc. The Company owns and operates Kali Tuna, which is an established Croatian based aquaculture operation raising Northern Bluefin Tuna in the Croatian part of the Adriatic Sea and Baja Aqua Farms, which is an established Mexico based aquaculture operation raising Northern Bluefin Tuna in the Pacific. The Company intends to become the leader in aquaculture for northern Bluefin tuna by acquisition and internal growth. The growth of the Company will be founded on the sustainable management of resources and economically sound practices, seeking opportunities resulting from market consolidation and scientific progress in the industry. We also intend to continue our research into closed cycle farming technology for Bluefin tuna which has produced encouraging results. For more information, please visit http://www.umamiseafood.com. Notice Regarding Forward Looking Statements This press release contains projections and forward-looking statements, as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and can include, without limitation, statements based on current expectations involving a number of risks and uncertainties and which are not guarantees of future performance of the Company. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including (i) adverse market conditions; (ii) any adverse occurrence with respect to the farmed seafood industry generally or the businesses of Kali Tuna andBaja specifically; and (iii) changes in the regulatory environment. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Although the Company believes that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors set forth in the Company's Annual Report on Form 10-K filed on October 22, 2010, and other reports filed or to be filed from time-to-time with theSecurities and Exchange Commission. ___________________________________________________________________________ Visit www.OTCtipReporter.com Also, you can receive up to the minute stock alerts via our Twitter page: http://twitter.com/#!/OTCtipReporter Get the BUZZ on all of Wall Street's Hottest stocks Free! About OTCtipReporter.com OTCtipReporter.com alerts investors to promising small cap companies, many (if not all) are overlooked by your run of the mill Wall Street investment advisors. At OTCtipReporter.com, we know it is easier to find a stock that can go from $0.01 - $0.50 in days or weeks, than it is to find a stock that can go from $1.00 - $50.00 in months or years. OTCtipReporter.com provides its subscribers with comprehensive public information and due diligence for small companies with huge potential. While many of the other investment newsletters talk a big game, at OtctipReporter.com we let our research do the talking! We invite you to give us a try and sign up for free today at: http://www.OTCtipReporter.com We do the Research, You Reap The Profits. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by OTC Tip Reporter. Please be advised that the information provided May or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed. To view a complete disclaimer, visit: http://www.otctipreporter.com/disclaimer.htm Let OTC Tip Reporter help advertise for your company using our effective awareness campaigns. If you're Interested in telling your story, we can help. Contact us at [email protected] To feature your publicly traded company in our alerts, email us at: [email protected] CONTACT: CONTACT: OTC Tip Reporter Tel: +1 347 829 7044 e-mail: [email protected] WWW: http://www.OTCtipReporter.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected])). (c) 2011 M2 COMMUNICATIONS |